Scientific Activism in the News

Today's New York Times includes a profile of drug safety advocate Dr. Steven E. Nissen by medical business writer Stephanie Saul:

His questioning of the safety of the Avandia diabetes medication in late May, for example, prompted a federal safety alert and led to a sales decline of about 30 percent for the drug, which brought in $3.2 billion for GlaxoSmithKline last year. Now, with a federal panel soon to decide whether it can remain on the market, Avandia's future is uncertain.

The drug is the latest example of why Dr. Nissen, 58, whose day job is chairman of cardiovascular medicine at the Cleveland Clinic, has emerged as a Naderesque figure and the nation's unofficial arbiter of drug safety.

Admirers laud him not only for raising safety questions about Avandia, but also for sounding early warnings about the painkiller Vioxx, as well as other drugs. By digging deeply into companies' own clinical trial data -- information that used to be available only to federal drug regulators who did not always mine it as aggressively -- Dr. Nissen is among a new cadre of activist scientists demanding greater vigilance on drug safety.

(Emphasis added)

Check out the full article here.

Categories

More like this

In this blog post from Trusted.MD Network Keshav Chander MD asks "Why Do We Hesitate To Use Generic Drugs?" Among the responses he heard are:
Ezra Klein relays Jim Manzi's worry that public funding of drug trials
One thing that drove me nuts during the healthcare reform debate was the scare tactic of claiming that proposed legislation would result in rationing of healthcare.
Over the last year or so, the US FDA has grown tougher on withdrawing prescription and over-the-counter drugs that have not met the modern burden of proof for safety and efficacy that was officially required by the 1962 passage of the Kefauver-Harris amendments to the 1906 Federal Food and Drug A